SUBSCRIBE
SUBSCRIBE

BridgeBio LLC

NEWS
Biotech Bay
BridgeBio Launches QED Therapeutics With $65M and an Abandoned Novartis Cancer Program
BridgeBio stepped in to take over the drug and also launch a subsidiary, QED Therapeutics, to drive the development of infigratinib.
January 30, 2018
 · 
2 min read
 · 
Alex Keown
Biotech Bay
BioPharm Executive: Money Talk
Venture capital is hopping, attracted to some of the past several years’ successes.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
3 Biotechs That Could be Taken Out This Quarter
Business
Bay Area Startup BridgeBio Quietly Snags $135 Million From a Bunch of Wall Street Firms
September 13, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Business
Another Biotech is Born as Bay Area’s BridgeBio Pharma Launches Eidos Therapeutics With $27 Million
April 27, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Business
BridgeBio Pharma Announces Academic Collaboration with Baylor College of Medicine to Advance Potential Therapies to Treat Genetic Diseases
July 21, 2022
 · 
4 min read
Drug Development
BridgeBio Pharma Announces Positive Phase 1 Data and Phase 2/3 Trial Design for BBP-711, a Potentially Best-In-Class GO Inhibitor for Primary Hyperoxaluria Type 1 (PH1) and Recurrent Kidney Stone Formers
June 27, 2022
 · 
7 min read
Drug Development
BridgeBio Pharma Announces Early Positive Data for BBP-812, its Investigational AAV9 Gene Therapy for Canavan Disease
June 22, 2022
 · 
9 min read
Drug Development
BridgeBio Pharma Shares Positive Phase 2b Data and Announces Pivotal Study Design for Phase 3 Trial of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1)
June 13, 2022
 · 
12 min read
Drug Development
BridgeBio Pharma Affiliate Venthera Presents Preliminary Results from Clinical Trial of VT30 (BBP-681) for Venous, Lymphatic, and Venolymphatic Malformations
June 10, 2022
 · 
5 min read
Drug Development
BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference
June 9, 2022
 · 
8 min read
Biotech Bay
BridgeBio Pharma to Participate in June 2022 Investor Events
June 6, 2022
 · 
1 min read
Drug Development
BridgeBio Pharma Presents Positive Phase 1 Data in Healthy Volunteers, Advancing Development of BBP-671 for Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Organic Acidemias
May 26, 2022
 · 
7 min read
Business
BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
May 20, 2022
 · 
9 min read
Business
BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
May 13, 2022
 · 
5 min read
Load More